Cencora (NYSE: COR) has signed a definitive agreement to acquire American Oncology Network (“AON”), the company said on 21 October 2026. The deal values AON at an enterprise value of $2.4 billion, Cencora disclosed in a filing with the US Securities and Exchange Commission.
Cencora shares fell 4.84% to $325.50 within hours of the announcement, according to Benzinga, even as the stock had gained 9.31% over the preceding 20 trading days.
What the $2.4bn figure actually covers
Cencora’s press release frames the transaction as expanding its “physician-led oncology MSO and support of care in communities across the country,” chief executive Robert P. Mauch said in the filing. AON is a physician-led network of more than 350 oncology providers across 21 states, and the deal would extend Cencora’s management-services platform into twelve additional states, according to the filed release.
The headline $2.4bn is not a single cash cheque. It comprises $2.3 billion payable at closing plus contingent value rights worth up to $100m tied to future conditions, Investing.com reported, citing the same release.
Why ‘remaining stake’ overstates the outcome
Some coverage, including a Benzinga wire note, described the transaction as Cencora acquiring the “remaining stake” in AON. That is only part of the picture. Cencora currently owns roughly 4% of AON’s equity and has agreed to buy the rest of the shares it does not already hold – but up to 25% of AON may instead roll into an equity stake held by selling stockholders, rather than being bought out entirely, according to a release reproduced by StockTitan.
That rollover structure means Cencora’s actual cash outlay looks closer to $1.7bn, not $2.3bn, and its resulting ownership stake in AON could land at roughly 75% rather than 100%. The gap between the “full buyout” framing in some headlines and the rollover mechanics in the underlying filing matters for anyone sizing up the deal’s dilution or debt impact.
The transaction still needs regulatory clearance and approval from AON stockholders, though AON’s board has already signed off, Investing.com reported. Cencora also raised its fiscal 2026 guidance alongside the announcement, now expecting adjusted diluted earnings per share of at least $17.90, the top of its previous $17.75-$17.95 range, citing strength in its US Healthcare Solutions segment.
A sell-off against a solid quarter
The share-price reaction sits awkwardly against Cencora’s recent financial performance. The group reported net income of $763.5m on revenues of $84.75bn for the quarter ended 30 June 2026, its most recent results ahead of the AON announcement, according to its 10-Q filing. That quarter capped a run in which Cencora’s net income has climbed from $420.8m in the quarter ended March 2024 to the current level, filings show.
FINRA’s daily short-sale data shows the ratio for Cencora shares running elevated in the fortnight before the deal was announced, peaking at 0.555 on 13 October and 0.544 on 9 October, before easing to 0.289 by 20 October. FINRA figures on their own don’t explain the move, but the pattern sits alongside a stock that rallied into the announcement only to give back ground once the rollover terms became clear.
What happens next
Closing is conditional on customary regulatory clearances and a vote by AON stockholders, with no completion date yet disclosed. Investors will be watching for further detail on how the equity rollover is structured once Cencora files additional transaction documents, and for confirmation of the raised earnings guidance when the company next reports.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
